Targeting cadherin-11 (cad-11) in rheumatoid arthritis (RA) could provide a complement to existing therapies, Adheron Therapeutics Inc. CEO Hari Kumar told BioWorld Today, and "that's exactly how we pitched it" to Roche AG, which is shelling out $105 million up front and potentially $475 million in milestone payments to take over the company, as toxicity studies continue ahead of phase II trials with SPD051.